常染色体显性多囊肾病的矿物质骨病
该研究在944例ADPKD与其他肾病患者中检测矿物质代谢标志物,并对20例ADPKD患者和17例健康人的骨活检行形态计量与免疫组化。ADPKD患者完整FGF23较高、总碱性磷酸酶较低,骨形成率降低;但ESKD因ADPKD所致者骨折风险不高于糖尿病或其他病因。
要点
- ADPKD患者总碱性磷酸酶较低、完整FGF23较高。
- ADPKD患者骨形成率与类骨质体积显著低于健康人。
- ESKD因ADPKD所致者骨折风险不高于其他病因。
核心结论
- ADPKD患者碱性磷酸酶更低、循环完整FGF23更高且骨形成率降低。
- ADPKD在ESKD中不伴更高骨折发生率。
研究设计与样本
- 在944例ADPKD及其他肾病患者中检测矿物质代谢标志物。
- 比较20例ADPKD患者与17例健康人的骨活检形态计量和免疫组化。
- 分析2002-2013年开始血液透析的ESKD成人,比较ADPKD与其他病因的骨折风险。
主要发现
- ADPKD患者较无ADPKD的CKD患者完整FGF23更高、总碱性磷酸酶更低。
- ADPKD患者类骨质体积/骨体积为0.61% vs 健康人1.21%。
- ADPKD患者骨形成率/骨表面积为0.012 vs 健康人0.026 μm3/μm2/day。
- ESKD因ADPKD所致者较糖尿病所致者年龄调整骨折发生率比为0.53(95%CI 0.31, 0.74)。
临床怎么用
- ADPKD患者应关注完整FGF23升高和碱性磷酸酶降低的矿物质代谢模式。
- ADPKD患者骨形成率降低,评估骨病时需考虑低转化状态。
- ESKD因ADPKD所致者骨折风险不高于其他病因,可据此调整监测重点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mice with disruption of Pkd1 in osteoblasts demonstrate reduced bone mineral density, trabecular bone volume and cortical thickness. To date, the bone phenotype in adult patients with autosomal dominant polycystic kidney disease (ADPKD) with stage I and II chronic kidney disease has not been investigated. To examine this, we characterized biochemical markers of mineral metabolism, examined bone turnover and biology, and estimated risk of fracture in patients with ADPKD. Markers of mineral metabolism were measured in 944 patients with ADPKD and other causes of kidney disease. Histomorphometry and immunohistochemistry were compared on bone biopsies from 20 patients with ADPKD with a mean eGFR of 97 ml/min/1.73m2 and 17 healthy individuals. Furthermore, adults with end stage kidney disease (ESKD) initiating hemodialysis between 2002-2013 and estimated the risk of bone fracture associated with ADPKD as compared to other etiologies of kidney disease were examined. Intact fibroblast growth factor 23 was higher and total alkaline phosphatase lower in patients with compared to patients without ADPKD with chronic kidney disease. Compared to healthy individuals, patients with ADPKD demonstrated significantly lower osteoid volume/bone volume (0.61 vs. 1.21%) and bone formation rate/bone surface (0.012 vs. 0.026 μm3/μm2/day). ESKD due to ADPKD was not associated with a higher risk of fracture as compared to ESKD due to diabetes (age adjusted incidence rate ratio: 0.53 (95% confidence interval 0.31, 0.74) or compared to other etiologies of kidney disease. Thus, individuals with ADPKD have lower alkaline phosphatase, higher circulating intact fibroblast growth factor 23 and decreased bone formation rate. However, ADPKD is not associated with higher rates of bone fracture in ESKD.
引用
- Gitomer B, Pereira R, Salusky IB, et al. Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2020. PMID: 32926884. doi:10.1016/j.kint.2020.07.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。